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ABSTRACT
The objective of the present research was to a develop colonic delivery system for budesonide based on
polymer blends of natural polysaccharides from Albizia procera and the GI-insoluble polymer ethylcellulose.
An emulsion solvent evaporation method was used for the preparation of the microspheres. In vitro drug
release was studied in a medium simulating gastrointestinal fluid and the mechanism of drug release was
determined using the Korsemeyer-Peppas equation. In vivo performance of the microsphere was evaluated in
acetic acid induced colitis in rats. Drug release studies showed that the microspheres with a procera gum-
ethylcellulose coating were able to resist premature drug release in the upper GI tract and yet were susceptible
to enzyme effects in the colon. Treatment of rats with a budesonide test formulation for five days significantly
attenuated the extent and severity of the cell damage and could thus be a promising system for the treatment
of ulcerative colitis.
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INTRODUCTION
Natural carbohydrate polymers such as plant
gums and mucilages have been widely explored
as devices for controlled delivery of medicinal
drugs. These polymers are abundant,
inexpensive, safe and available in a variety of
structures that can be easily modified
chemically and biochemically. In recent years
natural polysaccharides have received
considerable interest as carriers for the peroral
delivery of drugs to the colon. Several
polysaccharides such as pectin (1-2), guar gum
(3), chitosan (4), konjac glucomannan/xanthan
gum (5), amylase (6) and others have been
successfully evaluated for colonic delivery. The
colonic microflora secretes a number of
enzymes that are capable of hydrolytic cleavage
of glycosidic bonds including β-glucosidase, β-
galactosidase, α-arabinosidase, amylase,
pectinase and others. Natural polymer-based
colon targeted drug delivery systems rely on
anaerobic bacteria in the colon to degrade them
with the enzymes resulting in the release of the
entrapped drugs (7). In fact, these microflora
activated delivery systems are considered to be
*
Corresponding author: Lalduhsanga Pachuau, Department of   
  Pharmacy, Regional Institute of Paramedical and Nursing
  Sciences, Aizawl, 796017, India, E-Mail: aduhapc@gmail.com
This Journal is © IPEC-Americas Inc September 2014 J. Excipients and Food Chem. 5 (3) 2014 -  161 
                                   DOWNLOAD FREE FROM HTTP://OJS.ABO.FI/JEFC 
This material MAY NOT be used for commercial purposes - see Creative Commons Attribution licence
Original Article
most promising and a preferable means of
achieving targeted delivery of drugs to the
colon since the marked increase in the bacteria
population and its associated enzymes are
independent of gastrointestinal (GI) transit time
or pH (8).
Biodegradable natural polysaccharides used in
colonic drug delivery can have limitations. The
main drawback with using natural polymers
alone, in their native form, is their inherent
solubility and swelling properties in aqueous
media (9). This solubility and swelling often
results in the absorption or degradation of the
active ingredient in the upper GI tract which is
the main obstacle that must be circumvented
for successful colonic drug delivery (10). A
commonly employed approach to alleviate this
problem is to structurally modify the
polysaccharides or to blend them with other
functional polymers such as GI insoluble or pH
sensitive polymers.
The present study was carried out to formulate
and evaluate a multi-particulate system for
colon-specific drug delivery system using a
blend of natural polysaccharide from Albizia
procera and a GI insoluble ethylcellulose.
Multiparticulate dosage forms based on pellets,
granules, microspheres or nanoparticles offer
several advantages over a single unit system for
colon specific delivery of drugs. Due to their
smaller particle size, these systems are capable
of passing through the GI tract more easily,
resulting in less inter- and intra-subject
variability (11).
Albizia procera (Roxb.) Benth is a fast growing,
medium sized tree known to exude gums in
small transparent tears and vermiform pieces
(12). It has recently been reported that the
physicochemical properties of this gum exudate
(13). Ethylcellulose, being hydrophobic in
nature, does not readily allow water penetration
across the coating and avoids premature film
dissolution in the upper GI tract (14-15). The
main reason for selecting Albizia procera gum, an
arabinogalactan, in this study was because of
the known biodegradation of arabinogalactans
in the colon by the colonic microflora since
these microorganisms produce a wide range of
enzymes including α-arabinosidase, β-galacto-
sidase and so on. (16-17). 
Budesonide is a novel gluccocorticoid which is
highly effective in the treatment of irritable
bowel disease (IBD) due to its greater topical
anti-inflammatory activity than many other
gluccocorticoids. Due to the rapid, near
complete first-pass hepatic conversion to its
metabolites, the systemic effects of budesonide
are significantly less than for other conventional
corticosteroids which make it an ideal candidate




Budesonide (Batch No. B110263) was received
as gift from Cipla, Baddi, India. Ethylcellulose
(18-22 cps grade, Lobachemie) was used as
supplied. Albizia procera gum exudates
(Authenticated at the Department of Forestry,
School of Earth Sciences, Mizoram University)
were collected by hand picking in Mizoram
(India) during the month of January-March and
purified as described previously (13). Tween 80
LR was procured from Sd-Fine Chem. Ltd.,
India and used as received. All other chemicals




FTIR spectroscopy was performed to assess the
compatibility of budesonide with the polymer.
Samples were taken at 1:100 ratio with KBr and
mixed uniformly in a porcelain dish. About
10 mg of the mixed sample was transferred into
sample holder and pressed using a hydraulic
press to make a smooth surface. The
percentage transmittance was recorded between
This Journal is © IPEC-Americas Inc September 2014 J. Excipients and Food Chem. 5 (3) 2014 -  162 
                                   DOWNLOAD FREE FROM HTTP://OJS.ABO.FI/JEFC 
This material MAY NOT be used for commercial purposes - see Creative Commons Attribution licence
Original Article
400 and 4000 cm-1 on FTIR spectrophotometer
(IR Prestige-21, Shimadzu).  FTIR Spectrum
for budesonide, the dried procera gum, the
drug-procera gum mixture and the microsphere
formulation F3 was recorded for analysis.
Thermogravimetric analysis (TGA)
To study the possible interaction between
budesonide and polymer thermogravimetric
analysis was performed by TGA (Pyris TGA,
Perkin Elmer) between 40EC and 855EC at a
heating rate of 10EC/min while nitrogen
purging was maintained at 20 ml/min. For each
analysis, about 6 mg of the sample was put into
the aluminium sample pan and sealed. An
empty aluminium pan was used as reference,
and the thermograms were recorded for the
drug, procera gum, drug-procera gum mixture
and microsphere formulation F3.
Formulation and in vitro evaluation of
microspheres
Preparation of the microspheres
The microspheres were prepared using an
emulsion solvent evaporation technique using
the formulation shown in Table 1. The required
amount of ethylcellulose was dissolved in 20 ml
of acetone and a given amount of the drug and
procera gum were dispersed in it and stirred for
approximately 10 minutes. Then the polymer
drug dispersion was poured into 60 ml of light
liquid paraffin containing 2% of Tween 80. The
whole system was then stirred for about 5
hours at 900 RPM. After stirring was complete,
the liquid paraffin (light) was decanted off and
the microspheres  formed  were collected by 
filtration and washed with n-hexane to
completely remove the remaining oil, and tray-
dried at 50EC overnight.
Encapsulation efficiency
The amount of budesonide entrapped in the
microsphere was determined by extraction in a
solvent system comprising of methanol-water
(80:20). A sample of microspheres weighing
50mg was taken, crushed and powdered
followed by extraction in the solvent by stirring
for about 2 hours. The solution was filtered and
after suitable dilution, the content of
budesonide was determined using a Waters
HPLC system with a UV/Visible detector
(2489, Waters). The budesonide determination
was modified from a previously developed
method (18) and validated accordingly. Briefly,
the analysis was carried out using a Symmetry
C18 Column (dimension = 150x4.6 mm and
particle size 5µm, Waters) at a wavelength of
244 nm. 20 µl of the sample was injected and
methanol-water (80:20) was used for the mobile
phase at a flow rate of 0.8 ml/min. Data
acquisition and processing were performed by
using Empower 2 software (Waters). The
percentage of encapsulation was calculated
using equation 1.
Eq. 1
Encapsulation  efficiency   
                            
Experiment  Drug Content
Amount of  drug  added  in  the  formulation




The particle size of the microspheres was
determined by  microscopy.  The  ocular micro- 






SIZE (µm) ± SD
% ENCAPSULATION (%) ± SD
F1 9 mg 1000 mg 200 mg 566.80 ± 21.91 68.07 ± 1.98
F2 9 mg 900 mg 300 mg 556.66 ± 16.57 69.50 ± 1.02
F3 9 mg 600 mg 600 mg 534.44 ± 12.54 73.42 ± 2.88
F4 9 mg 300 mg 900 mg 488.88 ± 13.02 76.62 ± 4.82
F5 9 mg 200 mg 1000 mg 482.49 ± 06.58 76.60 ± 4.46
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meter was calibrated using stage micrometer
and each division of the ocular micrometer was
measured in micrometers. For each batch of the
microspheres, 100 particles were counted at 10x
magnification in triplicate from the same field.
Scanning electron microscopy
The shape and surface characteristics of
selected microspheres was analyzed using
scanning electron microscopy (JSM-6360, Jeol).
Samples were mounted on the aluminium stub
and photomicrographs of the microspheres
were taken after sputter coating with a thin
layer of gold. The quality of the microspheres
with respect to surface properties, and the
nature and size of pores developed on the
surface was evaluated. 
In vitro release studies
The in vitro release of budesonide from the
microspheres was performed using USP
Apparatus I (rotating basket) at a rotation speed
of 50 RPM (USP Dissolution Test Apparatus,
ACMAS Technocrat, India). 400 mg of
budesonide-containing microspheres from each
batch were placed in 250 ml of dissolution
medium which was maintained at 37±0.5EC.
The release study was performed in 250 ml
0.1 N HCl for the first 2 hours, followed by
250 ml of pH 6.8 Phosphate buffer for another
3 hours and finally 250 ml of pH 7.4 Phosphate
buffer to a total of 24 hours to simulate the
gastro-intestinal pH condition. About 2 ml of
the dissolution medium was withdrawn at
predetermined time intervals and replaced with
the same volume of fresh dissolution medium
and analyzed using the HPLC method
described earlier. 
In vitro release study in presence of rat cecal
content
Rat cecal content was prepared by the method
reported previously (19). Dissolution medium
containing 2% rat cecal content were prepared
in pH 7.4 phosphate buffer which had
previously been deoxygenated with N2 to
provide anaerobic conditions. Drug release
from the microspheres in the physiological
environment of colon was assessed by
performing drug release studies in the rat cecal
content medium. In this case, dissolution study
was performed in 0.1N HCl for the first two (2)
hours followed by pH 6.8 phosphate buffer for
the next three (3) hours. Finally, pH 7.4
phosphate buffer containing 2% rat cecal
content was used and the study was continued
for up to 24 hours. At different time intervals,
2 ml of the dissolution medium was withdrawn
and replaced with the same volume of the fresh
dissolution medium and analyzed by the HPLC
method.
In vitro drug release kinetics
To determine the release mechanism from the
microspheres, in vitro the drug release data were









Where, kk is the kinetic constant, Q4 is the
amount release at time t = 4, thus Qt / Q4 is
the fraction of drug released at time t. The
value n is the diffusion exponent which can be
used to characterize both mechanism for both
solvent penetration and drug release. The value
of n=0.5 indicates a Fickian Diffusion,
0.5<n<1.0 indicates anomalous (non-Fickian)
diffusion, n=1.0 indicates case II transport
(zero-order release) and n>1.0 indicates super
case II transport. Determining the correlation
coefficient assessed fitness of the data into
various kinetic models. The rate constants, for




Both male and female wistar rats (150 ± 50 g)
were used in the in vivo studies. They were
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housed under environmentally controlled
conditions with free access to water and
standard diet. The animal studies were carried
out according to the guidelines of CPCSEA,
Ministry of Environment & Forests,
Government of India and the study protocol
was approved by the Institutional Animal
Ethics Committee of Dibrugarh University,
India (Reg. No. 1576/GO/a/11/CPCSEA,
India).
Induction of colitis
Colitis was induced according to the method
described previously (21-22). Briefly,  following
a 24 hour fast, the rats were slightly
anaesthetized with ether, and then a medical-
grade polyurethane tube (external diameter 2
mm) was inserted into the anus and the tip was
advanced to 8 cm proximal to the anus verge.
Acetic acid (2 ml, 4% v/v in 0.9% saline) was
instilled into the colon through the tube for 30
seconds, after which the fluid was withdrawn.
The animals were left with free access to water
and pellets until the experiment was finished.
Administration of microspheres
The animals were divided into 6 groups of six
as follows:
 
1. A normal group (No induction of colitis)
which received 2 ml of 0.9 % saline by rectal
route.
2. A control group which did not receive any
treatment after induction of colitis.
3. A placebo group which received an oral
placebo dose of procera gum-ethylcellulose
microspheres without drug (blank
microspheres).
4. A vehicle group which received only 0.5 ml
of the vehicle, 1% Sodium Carboxymethyl
cellulose (Na CMC) orally.
5. A standard group which received marketed
product of budesonide microspheres (Budez
CR®) orally at 300 µg/kg dose of
budesonide.
6. A the test group which received formulation
F3 of procera gum-ethylcellulose coated
budesonide microspheres at 300 µg/kg dose
of budesonide.
The placebo (Blank), standard (Budez CR®) and
test microspheres (F3) were suspended in 0.5
ml of 1% Na CMC as per the dose calculated
(300 µg/kg) and administered orally to the rats
by feeding tube. Drug treatment was started 48
hours after colitis was induced where sufficient
time was given for the full development of
colitis and treatment was given once daily for 5
consecutive days.
Assessment of colitis
Twenty four hours after administration of the
last dose of the formulations, the rats were
sacrificed using a high dose of ether and a
midline incision was made in the abdomen. The
8 cm distal segment of the colon was removed,
washed and wet weight/length (g/cm) ratios
were obtained as criterion of injury (23). The
macroscopic appearance of the colonic mucosa
was scored according to an arbitrary scale
ranging from 0 – 3 as follows: 0 = no
macroscopic change, 1 = erythema &
inflammation without ulcer, 2 = inflammation
& ulcer, 3 = ulcer with necrosis. Inflammation
and ulcer surface area were measured and ulcer
index was calculated from the macroscopic
evaluation using the following equation:
Eq. 3
Ulcer Index  Ulcer  area  (sq.cm)   
                                                Macroscopic   Score
 
Histopathological study was performed by
fixing sections of colon specimens in phosphate
buffered formalin solution (10 %), embedded
in paraffin stained with haemotoxylin and eosin
and evaluated by light microscopy at suitable
magnification to observe and study the
morphological changes.
Statistical analysis
Statistical analysis was performed using
computer software SigmaStat 2.03 (SPSS,
USA). Analysis of variance /Tukey Test was
performed to compare the effects of different
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Figure 2 TG curves of (A) Budesonide, (B) Procera gum,
(C) Solid admixture of the drug with procera gum and (D)
Microsphere formulation F3
Figure 1 FTIR spectra of (A) Budesonide, (B) Procera
gum, (C) Solid admixture of the drug with procera gum and
(D) Microsphere formulation F3
polymers on physical and drug release
properties of the microspheres. The
susceptibility of procera gum coating to the
enzymatic action of colonic bacteria was
assessed by continuing the drug release studies
in a medium with 2% rat cecal content after
completing 5 hours of study in simulated gastric
and small intestinal media. The same software
was also used for the statistical analysis of the in
vivo studies.
RESULTS AND DISCUSSION
The microspheres were prepared following the
emulsion solvent evaporation method using
Tween 80 to help stabilize the emulsion. The




Figure 1 shows the FTIR spectra of
budesonide, procera gum, the drug-procera
gum mixture and the microsphere formulation
F3. A typical FTIR spectrum of budesonide
should showed characteristic O-H stretching
peak at 3378 cm-1 , C-H stretching peak at 2935
cm-1, and C=O stretching peaks at 1720 and
1659 cm-1 (24). These typical peaks were
observed for the budesonide sample (A) at
3483.44 cm-1(O-H stretch), 2935.66 cm-1 (C-H
stretch), 1716.65 cm-1 and 1658.78 cm-1 (C=O
stretch). In the IR spectrum of budesonide with
the polymer physical mixture (C), typical peaks
for budesonide at 3321.42 cm-1 (O-H stretch),
2935.66 cm-1 (C-H stretch), 1716.65 cm-1 and
1658.78 cm-1 (C=O stretch)  were still observed
confirming the presence of these functional
groups in the physical mixture and the
compatibility of the drug with the procera gum.
The spectrum for microsphere formulation F3
also showed budesonide peaks at 3312.56 cm-1
(O-H stretch), 2935.66 cm-1 (C-H stretch) and
1710.33 cm-1 and 1643.35 cm-1 (C=O stretch).
Thermogravimetric analysis
TG curves for the samples are shown in
Figure 2. The thermogram for budesonide (A)
showed a single endothermic weight loss
occurring in between 235.81EC and 486.59EC.
There was a significant weight loss of 82.54%
during this event. The melting point of
budesonide is around 220-235EC which
correlates well with the TGA thermogram. The
thermogram for procera gum (B) showed two
endothermic events. The first event occurred in
between 49.15EC and 145.73EC with 7.08%
weight loss and may be attributed to
evaporation of water. The second one occurred
This Journal is © IPEC-Americas Inc September 2014 J. Excipients and Food Chem. 5 (3) 2014 -  166 
                                   DOWNLOAD FREE FROM HTTP://OJS.ABO.FI/JEFC 
This material MAY NOT be used for commercial purposes - see Creative Commons Attribution licence
Original Article
Figure 3 Scanning electron micrographs of formulation F5
(A & B) and F2 (C & D)
between 224.04EC and 406.77EC was assigned
to the characteristic decomposition of the
polysaccharide. There was a total weight loss of
56.08% during this second event. The TG
pattern of the drug and the polymer mixture
(C) also showed that two stages of degradation
occurred between 45.47EC and 110.55EC with
9.72% weight loss which could be attributed to
the evaporation of water from the polymer.
The second event between 219.01EC and
405.57EC with 52.4% weight loss could be
attributed to a composite of the events
observed for budesonide and procera gum. The
TG thermograms for microsphere formulation
F3 (D) also showed two stages of weight loss
occurring between 42.80EC and 112.21EC with
10.48% weight loss and 221.85EC and
395.27EC with 54% weight loss. The
thermogram obtained supported well the results




The drug content in all the formulations was
between 6.13 mg in F1 and 7.02 mg in F5 as
given in the Table 1. The encapsulation
efficiency was in between 68.09 ± 4.51% and
78.02 ± 2.89 % with no statistically significant
difference (p>0.05) observed in all of the above
formulations with encapsulation efficiency.
Scanning electron microscopic studies
The emulsion solvent evaporation method is
the second most frequently used technique for
microencapsulation involving ethylcellulose (25)
and this method was used successfully here for
the production of the microspheres. Figure 3
shows the scanning electron micrographs of the
microspheres. It was observed that most of the
microspheres were spherical in shape and had
pores in the surface which may be due to the
gradual evaporation of the solvent during
stirring. However, these pores may be beneficial
for the release of budesonide from the
microspheres. It was observed that, as the
amount of ethylcellulose was increased in the
formulations from F1 to F5, the surface
became much smoother. The microsphere
formulations with higher proportions of
procera gum possessed a rougher surface.
Increased ethylcellulose concentration in the
coatings (accompanied by a corresponding
reduction in proportion of procera gum)
resulted in microspheres with better, smoother
surfaces. A possible reason for this may be the
disturbance of the continuity of ethylcellulose
coating membrane by the presence of procera
gum particles as reported for Eudragit S coated
pectin microspheres (26), a different polymer
system, which, however is prepared using the
same emulsion solvent evaporation method.
Average particle size
The average particle size was determined by
microscopic method using ocular eye piece
calibrated through a standard stage micrometer.
As given in Table 1, the average particle sizes
were between 567.88 ± 11.39 µm in F1 and
462.16 ± 06.05 µm in F5. The average particle
sizes tended to become smaller as the level of
ethylcellulose was increased. Significant changes
were observed (p<0.05) between formulations
F2 and F4, but not between F1 and F2 or F4
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Figure 4 Graph of % drug release versus time for different
formulations in dissolution medium containing rat cecal
contents (RCF1, RCF2, RCF3, RCF4 & RCF5) and without
rat cecal contents (F1, F2, F3, F4 & RCF5)
and F5. Normally, an increase in the viscosity
of the polymer solution results in an increase in
the size of emulsion droplets which ultimately
produces larger size microspheres (27).
However, the trend observed in this study
indicated that an increase in the amount of
ethylcellulose and the resultant increase in
viscosity, due to more ethylcellulose being
dissolved in the same volume of acetone,
subsequently produced smaller microspheres
with improved surface properties. This may be
attributed to the presence of procera gum in the
dispersed phase which may have affected the
emulsification process and altered the
continuity of the coating membrane as
indicated previously.
In vitro drug release
Simulated GI fluid
For successful colonic drug delivery, absorption
or degradation of the active ingredients in the
upper GI tract should be prevented or
minimized (10). The main drawback of using
natural polymers alone for colon specific drug
delivery is their inherent swelling and solubility
in aqueous media which results in the drug
being released before the colon is reached (2).
Blending natural polysaccharides, such as
procera gum with GI tract insoluble
ethylcellulose is therefore expected to produce
polymeric films with reduced drug permeability
in the stomach and small intestine (28). To
evaluate the performance of the developed
systems in achieving specific delivery of drugs
to the colon, in vitro dissolution testing was
performed with dissolution medium simulating
the pH conditions in the GI tract. Drug release
profiles for the different formulations are
shown in Figure 4. Release of budesonide in
acidic medium after 2 hours varied between
13.89% in F1 and 2.78% in F5. After 5 hours,
drug release was 35.80%, 29.03%, 13.13%,
8.58% and 8.15% in F1, F2, F3, F4 and F5
respectively. There were significant differences
in the dissolution time of budesonide (p<0.001)
between the different formulations after 24
hours in the simulated GI fluid. Previous
studies have indicated that, when the amount of
drug released in the initial 5 hours, is not more
than 10% (29) or less than 20% in 6 hours (15),
the system is considered to be capable of
functioning as a colonic drug delivery system.
After 24 hours dissolution study, the total
amount of drug released was more than 90% in
F1 and F2, 79% in F3 and around 40% in F4
and F5. The percentage of drug released in the
target area of the simulated colonic
environment over 24 hours was 62.82% for F1,
62.73% for F2, 65.99% for F3, 38.73% for F4
and 30.95% for F5. From the percent of
budesonide released after 5 hours, it is apparent
that formulations F3, F4 and F5 are capable of
preventing much of the drug from being
released in the physiological environment of the
stomach and intestine. However, the percentage
drug released after 24 hours from formulations
F4 and F5 was too low, or not sufficiently
rapid, for topical colonic delivery of
budesonide. To avoid the possible systemic
effects of budesonide and harness its superior
anti-inflammatory activity for treating IBDs, the
delivery system should ideally prevent the
release of the drug in the upper GI tract, while
providing a rapid release once it reaches the
colon. Formulations F3 and F4 appear to
achieve this target for colonic drug delivery
better than the other microsphere formulations.
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Medium with 2% rat cecal content
The susceptibility of procera gum-ethylcellulose
coating to the enzymatic action of colonic
bacteria was assessed by continuing the drug
release studies in 2% rat cecal content medium
after 5 hours study in simulated gastric and
intestinal fluids. The dissolution medium was
changed at the 6th hour to simulate the colon
arrival time under normal conditions. The
presence of 2% rat cecal content in simulated
colonic fluid showed evidence of slightly faster
drug release at different time periods when
compared with the release study without rat
cecal content. However, the difference in drug
release with or without rat cecal content was
not found to be significant in different
formulations of the microspheres (p=0.9605
for F1, p = 0.9498 for F2, p = 0.9122 for F3, p
= 0.9535 for F4 and p = 0.8563 for F5) when
they are treated statistically. This could be
attributed to the fact that the colonic bacterial
action of the rat cecal medium may not be
sufficient to degrade the gel barrier developed
in the system or the 2% rat cecal content used
may be too low in the in vitro system. With
other polysaccharide-based colonic drug
delivery formulations, such as tablets or cross-
linked polysaccharide microspheres, the whole
system is usually accessible to the colonic fluids.
In the present formulation, where a polymer
blend was used, the presence of ethylcellulose
in the coating also restricted to certain extent
the entry of the simulated colonic fluid, and this
may have led to reduced degradation of the
polysaccharide. However, the slightly increased
drug release observed with the medium
containing 2% rat cecal contents can be
considered as evidence that degradation of the
microspheres will take place in the colonic
environment. Also, as reported earlier, the
human cecal contents would be far better at
degrading this gel barrier (30). In the present
study, 2% rat cecal content was used to obtain
an overview on the susceptibility of the system
to the colonic enzymes, and a standard protocol
was available in the literature for its preparation
(19).
Release kinetics
The mechanism of drug release was determined
using the Korsemeyer-Peppas model and the
results are given in Table 2. The release
exponent ‘n’ calculated from the equation,
shows that in all the batches the ‘n’ values were
between 1.047 and 1.216. The ‘n’ value does
not differ significantly between the two
dissolution media taken for the in vitro release
study. The ‘n’ value for all the in vitro drug
release study was larger than 1.0 which indicates
that drug release follows super case II transport
where more than one specific mechanism was
involved in release of the drug from the
microspheres (31). For this type of transport,
the polymer relaxation is the rate-limiting step
to water transport (32). In general, the
contribution of polymer relaxation was higher
for the formulations with higher ‘n’ values. The
mechanism also explains the initial slow release
phase where only 13.89%, 10.10%, 5.39%,
2.65% and 2.78% of the drug were released in
F1, F2, F3, F4 and F5 respectively. This is
probably due to the slow hydration of the
polymer which resulted in incomplete
relaxation of the polymer chains. Insufficient
polymer hydration could be attributed to the
presence of ethylcellulose where pores/
channels did not develop quickly enough during
the initial stage. However, with time more pores
developed resulting in increased hydration of
the procera gum and subsequent relaxation.
The effect of procera gum relaxation became
more prominent which ultimately controlled
the release of the drug from the microspheres.
Table 2 Drug release kinetics
FORMULATION n r2 K
F1 1.047 0.981 1.170
F2 1.112 0.981 1.353
F3 1.084 0.966 1.558
F4 1.216 0.963 1.884
F5 1.103 0.984 1.855
In vivo studies
Acetic acid-induced colitis was chosen as a
method for ulcer induction because the formed
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Figure 5 Histopathological examination of the  colon (x45)
in (A) Normal group, (B) Control group, (C) Placebo group,
(D) Vehicle group, (E) Market product group and (F) Test
group
ulcer resembles human ulcerative colitis in
histology, eicosanoid production and excessive
oxygen-derived free radicals release by inflamed
mucosa (33). The histopathological features of
acetic acid treated rats included necrotic
destruction of mucosa and sub-mucosa, areas
of hemorrhage and diffuse inflammatory cell
infiltration in the mucosa. After 4% v/v acetic
acid was instilled into the colon, the animals
started to developed bloody diarrhea, the
animals were weak and their food intake was
also decreased which resulted in weight loss.
Macroscopic examination as shown in Figure 5
showed signs of severe hemorrhagic lesions and
inflammation as assessed by macroscopic
scores. Parameters such as colon wet
weight/length ratio, ulcer area, ulcer index and
macroscopic damage score were used to
evaluate the macroscopic damage of the colon
and these data are summarized in Table 3.
Results of the colon wet weight/length ratio
from the colitis induced groups showed that the
group treated with formulated test
microspheres (F3) exhibited the minimum
value of 0.269 g/cm. However, since there was
no statistically significant difference (p=0.255)
between the groups, it would not be
appropriate to use as an index of colonic
inflammation. Ulcer area, ulcer index and
macroscopic  score  were  significantly different












Normal 0.239±0.002 0.00 0.00
Control 0.323±0.015 9.40±1.69 10.86±1.21







Test drug 0.269±0.002 2.75±1.11 4.06±1.24
between the normal and negative control
groups. As shown in Table 3, animals treated
with the test formulation showed an attenuated
extent of the colonic injury with significantly
reduced ulcer area (p = 0.0026) when compared
to the control group. There was also slight
reduction of ulcer area in the Budez CR® , blank
microspheres, and vehicle treated groups when
compared to the control, but the reduction was
not statistically significant (p=0.0557 for Budez
CR® versus the control, p=0.1081 for blank
microspheres versus the control and p=0.1936
for vehicle versus the control groups).
Treatment of rats with the test budesonide
formulation for five days reduced the severity
of the colonic damage. The ulcer index, which
is calculated from the summation of the ulcer
area and the macroscopic score, was also
significantly reduced from 10.86±1.35 in the
untreated control group to 4.05 ± 0.63 in the
test group (p<0.001). However, the reduction
in ulcer area between control and other groups
was not statistically significant (p=0.0756 for
Budez CR® versus the control, p=0.0865 for
blank microspheres versus the control and
p=0.1964 for vehicle vs control).
CONCLUSION
A microsphere system for colonic delivery of
budesonide based on polymer blends of natural
polysaccharides from Albizia procera and
ethylcellulose was developed successfully. The
compatibility between the drug and the polymer
was established through FTIR and TGA
analysis. The appropriate blends of the
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polymers have the ability to limit the release of
drug in simulated gastric and small intestinal
conditions while maximizing drug release in the
colonic environment indicating its potential for
colonic drug delivery. In vitro analysis showed
that 1:1 ratio of procera gum-ethylcellulose (F3)
was the optimum formulation. The data
generated as an outcome of this research
demonstrates that ethylcellulose-procera gum
coated budesonide microspheres reduced the
severity of ulcerative colitis in acetic acid-
induced colitis in rats. 
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